A phase II study evaluating the safety and efficacy of sunitinib maleate in combination with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF [granulocyte colony-stimulating factor] as neoadjuvant chemotherapy for locally advanced or inflammatory breast cancer.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Sunitinib (Primary) ; Cyclophosphamide; Doxorubicin; Filgrastim; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; Inflammatory breast cancer
- Focus Therapeutic Use
- 28 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Jan 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.